BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murakami Y, Satoi S, Sho M, Motoi F, Matsumoto I, Kawai M, Honda G, Uemura K, Yanagimoto H, Shinzeki M. National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival. World J Surg. 2015;39:2306-2314. [PMID: 26013206 DOI: 10.1007/s00268-015-3096-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Kishi Y, Nara S, Esaki M, Hiraoka N, Shimada K. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. BJS Open 2019;3:327-35. [PMID: 31183449 DOI: 10.1002/bjs5.50130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Nagakawa Y, Hosokawa Y, Nakayama H, Sahara Y, Takishita C, Nakajima T, Hijikata Y, Kasuya K, Katsumata K, Tokuuye K, Tsuchida A. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. Cancer Chemother Pharmacol 2017;79:951-7. [DOI: 10.1007/s00280-017-3288-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
3 Nagakawa Y. ASO Author Reflections: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Is Combined Radiotherapy Necessary? Ann Surg Oncol 2019;26:1637-8. [PMID: 30783855 DOI: 10.1245/s10434-019-07245-7] [Reference Citation Analysis]
4 Kantor O, Talamonti MS, Wang C, Roggin KK, Bentrem DJ, Winchester DJ, Prinz RA, Baker MS. The extent of vascular resection is associated with perioperative outcome in patients undergoing pancreaticoduodenectomy. HPB 2018;20:140-6. [DOI: 10.1016/j.hpb.2017.08.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Okada K, Takahashi S, Sueda T. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol 2017;79:801-11. [PMID: 28314992 DOI: 10.1007/s00280-017-3281-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Einama T, Kamachi H, Tsuruga Y, Sakata T, Shibuya K, Sakamoto Y, Shimada S, Wakayama K, Orimo T, Yokoo H, Kamiyama T, Katoh N, Uchinami Y, Mitsuhashi T, Taketomi A. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma. Medicine (Baltimore) 2018;97:e11309. [PMID: 30075497 DOI: 10.1097/MD.0000000000011309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
8 Yamada S, Fujii T, Takami H, Hayashi M, Iwata N, Kanda M, Tanaka C, Sugimoto H, Nakayama G, Koike M, Fujiwara M, Kodera Y. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Surgery 2017;162:784-91. [DOI: 10.1016/j.surg.2017.04.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
9 Ushida Y, Inoue Y, Ito H, Oba A, Mise Y, Ono Y, Sato T, Saiura A, Takahashi Y. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Pancreatology 2021;21:130-7. [PMID: 33303373 DOI: 10.1016/j.pan.2020.11.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Mizumoto T, Toyama H, Asari S, Terai S, Mukubo H, Yamashita H, Shirakawa S, Nanno Y, Ueda Y, Sofue K, Tanaka M, Kido M, Ajiki T, Fukumoto T. Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Adenocarcinoma of the Body and Tail. Ann Surg Oncol 2018;25:638-46. [DOI: 10.1245/s10434-017-6274-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
11 Noda Y, Goshima S, Kawada H, Kawai N, Miyoshi T, Matsuo M, Bae KT. Modified National Comprehensive Cancer Network Criteria for Assessing Resectability of Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol 2018;210:1252-8. [PMID: 29629801 DOI: 10.2214/AJR.17.18595] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Lindemann J, du Toit L, Kotze U, Bernon M, Krige J, Jonas E. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. HPB (Oxford) 2021;23:173-86. [PMID: 33268268 DOI: 10.1016/j.hpb.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kato Y, Yamada S, Tashiro M, Sonohara F, Takami H, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. HPB (Oxford). 2019;21:1211-1218. [PMID: 30773450 DOI: 10.1016/j.hpb.2019.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Oba A, Kato T, Inoue Y, Wu YHA, Ono Y, Sato T, Ito H, Saiura A, Takahashi Y. Extent of venous resection during pancreatectomy-finding the balance of technical possibility and feasibility. J Gastrointest Oncol 2021;12:2495-502. [PMID: 34790410 DOI: 10.21037/jgo-21-129] [Reference Citation Analysis]
15 Bae JS, Kim JH, Joo I, Chang W, Han JK. MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer. Eur Radiol 2019;29:3714-24. [PMID: 30899975 DOI: 10.1007/s00330-019-06140-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
16 Hashimoto Y, Ishida M, Ryota H, Yamamoto T, Kosaka H, Hirooka S, Yamaki S, Kotsuka M, Matsui Y, Yanagimoto H, Tsuta K, Satoi S. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Pancreatology 2019;19:443-8. [DOI: 10.1016/j.pan.2019.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
17 Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Takahashi S, Sueda T. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol 2017;79:37-47. [PMID: 27878355 DOI: 10.1007/s00280-016-3199-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
18 Kondo N, Uemura K, Sudo T, Hashimoto Y, Sumiyoshi T, Okada K, Seo S, Otsuka H, Murakami Y, Takahashi S. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. Eur J Cancer 2021;159:215-23. [PMID: 34781169 DOI: 10.1016/j.ejca.2021.10.012] [Reference Citation Analysis]
19 Miyasaka Y, Ohtsuka T, Kimura R, Matsuda R, Mori Y, Nakata K, Kakihara D, Fujimori N, Ohno T, Oda Y, Nakamura M. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Ann Surg Oncol. 2019;26:1528-1534. [PMID: 30868514 DOI: 10.1245/s10434-019-07309-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
20 Makino I, Tajima H, Kitagawa H, Gabata R, Okazaki M, Shinbashi H, Ohbatake Y, Nakanuma S, Saito H, Yamaguchi T, Terai S, Okamoto K, Sakai S, Kinoshita J, Nakamura K, Ninomiya I, Fushida S, Ohta T. Verification of Resectability Status for Pancreatic Cancer: Radiological and Pathological Analysis of Patients Undergoing Pancreatoduodenectomy With Combined Resection of the Superior Mesenteric Artery. Pancreas 2022;51:35-40. [PMID: 35195593 DOI: 10.1097/MPA.0000000000001964] [Reference Citation Analysis]
21 Jiang B, Zhou L, Lu J, Wang Y, Liu C, Liang Z, Zhou W, You L, Guo J. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients with pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 2021;36:507-15. [PMID: 32875609 DOI: 10.1111/jgh.15244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
23 Murakami Y, Nakagawa N, Kondo N, Hashimoto Y, Okada K, Seo S, Otsuka H. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma. Pancreatology 2021;21:564-72. [PMID: 33526385 DOI: 10.1016/j.pan.2021.01.008] [Reference Citation Analysis]
24 Kimura N, Yamada S, Takami H, Murotani K, Yoshioka I, Shibuya K, Sonohara F, Hoshino Y, Hirano K, Watanabe T, Baba H, Mori K, Miwa T, Kanda M, Hayashi M, Matsui K, Okumura T, Kodera Y, Fujii T. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Cancers (Basel) 2020;13:E36. [PMID: 33374369 DOI: 10.3390/cancers13010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Nguyen AH, Melstrom LG. Use of imaging as staging and surgical planning for pancreatic surgery. Hepatobiliary Surg Nutr 2020;9:603-14. [PMID: 33163511 DOI: 10.21037/hbsn.2019.05.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Sho M, Murakami Y, Kawai M, Motoi F, Satoi S, Matsumoto I, Honda G, Uemura K, Yanagimoto H, Kurata M, Akahori T, Kinoshita S, Nagai M, Nishiwada S, Fukumoto T, Unno M, Yamaue H, Nakajima Y. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. J Hepatobiliary Pancreat Sci 2016;23:188-97. [DOI: 10.1002/jhbp.320] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]